At least 65 dead after Ebola outbreak confirmed in Democratic Republic of the Congo, officials say
Healthcare workers walk outside the Ebola treatment centre in Beni, eastern Democratic Republic of the Congo. (2019). (Photo by Sally Hayden/SOPA Images/LightRocket via Getty Images)
(NEW YORK) – An Ebola outbreak has been confirmed in the Ituri province in Democratic Republic of the Congo, according to Africa Centres for Disease Control and Prevention.
As of the latest update, about 246 suspected cases and 65 deaths have been reported, mainly in Mongwalu and Rwampara health zones, officials said.
Africa CDC said that preliminary lab results from the Institut National de Recherche Biomédicale (INRB) have detected Ebola virus in 13 of 20 samples tested. Four deaths have been reported among laboratory-confirmed cases.
The latest outbreak comes around five months after Congo’s last Ebola outbreak was declared over after more than 40 deaths.
“Africa CDC is closely monitoring the situation and convening an urgent high-level coordination meeting today with the DRC, Uganda, South Sudan and global partners to reinforce cross-border surveillance, preparedness and outbreak response efforts,” officials said in a statement Friday.
-ABC News’ Rashid Haddou contributed to this report
Pfizer logo (Photo Illustration by Nikolas Kokovlis/NurPhoto via Getty Images)
(NEW YORK) — Earlier this week, pharmaceutical company Pfizer and its partner Valneva announced that an experimental Lyme disease vaccine showed more than 70% efficacy in late-stage clinical trials.
The candidate, PF-07307405, showed 73.2% efficacy in reducing confirmed cases of Lyme disease cases after the fourth and final dose was administered when compared to a placebo.
However, the companies said there were fewer than anticipated cases of Lyme disease during the trial period and the study missed an important benchmark.
The trial did not reach its primary endpoint to provide an idea of how the results of this vaccine would turn out in a much larger population of people. Only with re-analyzing the data were researchers able to generate a statistically meaningful result.
Experts in tick-borne diseases told ABC News they still need to see the full data from the trials and that it’s early to determine what kind of impact the vaccine will have — but they add that results are “encouraging.”
“There are many other companies that are trying to develop something, but those are years and years and years away from being anywhere close to being marketed,” Dr. Gene Shapiro, a professor of pediatric infectious diseases and epidemiology of microbial diseases, told ABC News. “So, this vaccine was very similar to the vaccine that we know worked in the past. I think we have to pay attention to [this new one].”
Lyme disease is a bacterial infection that is spread through the bite of blacklegged ticks, also known as deer ticks, according to the Centers for Disease Control and Prevention (CDC).
Symptoms include fever, headache, fatigue and a skin rash known as erythema migrans, the CDC says. If left untreated, the infection can spread to joints, the heart and the nervous system.
More than 89,000 cases of Lyme disease were reported to the CDC by state health departments and the District of Columbia in 2023, according to the latest data available from the federal health agency. Estimates suggest about 476,000 Americans may be diagnosed and treated for Lyme disease annually.
Currently, no vaccine for Lyme disease is available in the U.S. Previously, a vaccine was available, but it was discontinued in 2002, according to the CDC.
“The uptake was poor. The sales were poor, and the company decided to stop selling it,” Shapiro said. “The currently developed vaccine [by Pfizer and Valneva] is very, very similar to that vaccine, with very minor modifications.”
Dr. Martin Becker, a clinical associate professor in the department of medicine at NYU Grossman Long Island School of Medicine, added that there were concerns raised, including about vaccine recipients having joint problems but several studies examining a link failed to find an association.
Becker said there have been many clinical trials underway “but this one that Pfizer just announced, I believe, is the one that’s been most advanced,” he told ABC News. “We were eagerly awaiting results from this large Phase III trial. Other previous trials were already published showing the safety and immunogenicity [of the vaccine].”
Pfizer and Valneva said they are planning to file for approval with the U.S. Food and Drug Administration, with Pfizer telling ABC News that the trial results show there is a level of protection against Lyme disease.
“It doesn’t mean it doesn’t work, but it does mean — if we had higher numbers of incidence of infection — we would be more confident about the degree of protection. It’s very encouraging,” Becker said.
Questions remain about whether the vaccine, if approved, will have higher uptake than the previous vaccine did decades earlier.
Shapiro said there might be more uptake with this vaccine if stronger recommendations are made. At the time the old vaccine was approved by federal regulators, Shapiro said the recommendation from the CDC’s Advisory Committee on Immunization Practices was to consider the shot for those at higher risk, but it was not recommended for those at low or no risk.
“It was not a very strong recommendation,” Shapiro said. “And I think there was less awareness of Lyme disease. So, most likely, [the newer vaccine] would get a stronger endorsement today.”
Stock photo of people commuting on e-bikes and scooters. (Maskot/STOCK PHOTO/Getty Images)
(NEW YORK) — E-bikes and e-scooters led to a growing number of trauma injuries at one New York City hospital, according to a new study published Wednesday.
About 7% of all trauma visits between 2018 and 2023 at Bellevue Hospital Center were due to micromobility injuries. Micromobility is the use of small, lightweight and low-speed modes of transportation such as bicycles, e-bikes and e-scooters.
The study showed a growing share of patients who sustained these injuries had accidents linked to e-bikes or e-scooters.
Hospital data showed that, by 2023, over half of all trauma cases related to bikes or scooters involved an e-bike or e-scooter, an increase from just 8% in 2018, according to the study, published in the journal Neurosurgery.
The most common type of mechanism involved a collision with a motor vehicle followed by falls from the bike or scooter.
Bellevue is a Level 1 Trauma center in a large metropolitan city, designed to treat the worst kinds of injuries. Over the study period, about 30% of patients suffered a traumatic brain injury, 26% had injury to the skull or face and 50% required surgery.
“Our study shows that micromobility injuries are producing serious brain and spinal trauma that demands neurosurgical care at a scale we haven’t seen before,” corresponding study author Dr. Hannah Weiss, a resident in the Department of Neurosurgery at NYU Grossman School of Medicine, said in a press release. “In a busy urban setting, we are seeing more and more of these injuries firsthand.”
Most patients seen for these injuries, nearly 69%, needed to be admitted to the hospital and nearly a third needed intensive care.
The majority of patients stayed at least three days in the hospital. Pedestrians who were struck had higher rates of traumatic brain injuries and were more likely to be admitted for intensive care.
“The data point to actionable solutions — helmet use, safer bike lane design and enforcement — that could prevent many of these injuries and better protect both riders and pedestrians, who in our study often sustained even more severe brain injuries than the riders themselves,” Weiss said.
About 20% of patients were intoxicated with alcohol, only 31% were using a helmet and injuries were more likely to occur in the evening hours, according to the study.
“Our findings make clear that urban infrastructure must continue to improve to keep pace with the rapid rise of electric bikes and scooters,” Dr. Paul P. Huang, an associate professor in the department of neurosurgery at NYU Grossman School of Medicine and chief of neurosurgery at NYC Health + Hospitals/Bellevue, said in a press release.
“Future studies should track these injuries across multiple cities and measure whether protected bike lanes, helmet programs, and speed enforcement actually reduce the number of brain and spine surgeries we perform,” Huang added,
Jade A. Cobern, MD, MPH, is a practicing physician, board-certified in pediatrics and general preventive medicine, and is a fellow of the ABC News Medical Unit.
Dr. Casey Means, nominee for the medical director in the Regular Corps of the Public Health Service and U.S. surgeon general, testifies at a Senate Health, Education, Labor and Pensions Committee hearing on Capitol Hill on February 25, 2026 in Washington, DC. Andrew Harnik/Getty Images
(WASHINGTON) — President Donald Trump’s surgeon general nominee, Dr. Casey Means, indicated she supports vaccines but stopped short of recommending certain shots during her confirmation hearing before the Senate Health, Education, Labor and Pensions (HELP) committee on Wednesday.
Means, who has a medical degree but does not hold an active medical license, appeared hesitant to say that some vaccines, such as the flu vaccine, prevent serious disease.
When asked by HELP committee chair Sen. Bill Cassidy, R-La., if she would encourage mothers to vaccinate their children with the measles, mumps and rubella (MMR) vaccine amid widespread illness in the U.S., Means said, “I absolutely am supportive of the measles vaccine, and I do believe vaccines save lives and are important part of the public health strategy.”
However, she stressed personal autonomy and said each patient or parent needs to have a conversation with their doctor or pediatrician before taking any medication.
Later in the hearing, Sen. Tim Kaine, D-Va., asked Means for her opinion on the efficacy of the flu vaccine.
“Do you believe that there is evidence that the flu vaccine prevents serious disease and prevents hospitalization or deaths in children?” Kaine said.
“I believe that all patients should talk to their doctor–” Means began answering.
“And so do I, and that’s not what I’m asking,” Kaine interjected.
“I support the CDC’s guidance on the flu vaccine,” Means replied, adding that she believes the shot reduced the risk of hospitalization “at the population level.”
Earlier this year, the Centers for Disease Control and Prevention announced that it was changing the childhood immunization schedule, removing the universal recommendation for multiple shots, including the flu vaccine.
Means was originally scheduled to testify before the HELP committee in October, but her appearance was postponed for four months after she went into labor.
If confirmed, Means would become the nation’s top doctor, leading more than 6,000 members of the U.S. Public Health Service, including physicians, nurses, scientists and engineers working at various federal health agencies.
Means’ views largely mirror those of Health and Human Services Secretary Robert F. Kennedy Jr., with a focus on tackling the chronic disease epidemic, creating a healthier food supply and expressing vaccine skepticism.
This is a developing story. Check back for updates.
ABC News’ Youri Benadjaoud and Arthur Jones II contributed to this report.
